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Abstract
Objective: To investigate the effect of all-trans retinoic acid(ATRA) on the proliferation and differentiation of brain
tumor stem cells(BTSCs) in vitro.
Methods: Limiting dilution and clonogenic assay were used to isolate and screen BTSCs from the fresh specimen
of human brain glioblastoma. The obtained BTSCs, which were cultured in serum-free medium, were classified into
four groups in accordance with the composition of the different treatments. The proliferation of the BTSCs was
evaluated by MTT assay. The BTSCs were induced to differentiate in serum-containing medium, and classified into
the ATRA group and control group. On the 10th day of induction, the expressions of CD133 and glial fibrillary
acidic protein (GFAP) in the differentiated BTSCs were detected by immunofluorescence. The differentiated BTSCs
were cultured in serum-free medium, the percentage and the time required for formation of brain tumor spheres
(BTS) were observed.
Results: BTSCs obtained by limiting dilution were all identified as CD133-positive by immunofluorescence. In
serum-free medium, the proliferation of BTSCs in the ATRA group was observed significantly faster than that in the
control group, but slower than that in the growth factor group and ATRA/growth factor group, and the size of the
BTS in the ATRA group was smaller than that in the latter two groups(P < 0.01). In serum-containing medium, the
expression percentages of CD133 and GFAP in the differentiated BTSCs were (2.29% ± 0.27%) and (75.60% ± 4.03%)
respectively in the ATRA group, and (7.05% ± 0.49%) and (12.51% ± 0.77%) respectively in the control group. The
differentiation rate of BTSCs in the ATRA group was significantly higher than that in the control group (P < 0.05),
but there was still CD133 expressed in the ATRA group. The differentiated BTSCs could re-form BTSs in serum-free
medium. The percentage of BTS formation in the ATRA group was(4.84% ± 0.32%), significantly lower than that in
the control group (17.71% ± 0.78%) (P < 0.05), and the time required for BTS formation in the ATRA group was
(10.07 ± 1.03)d, significantly longer than that in the control group (4.08 ± 0.35)d (P < 0.05).
Conclusion: ATRA can promote the proliferation and induce the differentiation of BTSCs, but the differentiation is
incomplete, terminal differentiation cannot be achieved and BTSs can be formed again.
Introduction
All-trans retinoic acid (ATRA) is one of the strongest
and most thoroughly studied differentiation inducers. It
can induce the differentiation and apoptosis of a variety
of tumor cells including glioma cells[1]. The concept of
tumor stem cells suggests that the tumor stem cells are
a cause of the formation, development and post-treat-
ment relapse of tumors, as brain tumor stem cells
(BTSCs) have a high potential of self-renewal and
proliferation, which enables them to be resistant to
chemo- and radiotherapies, so BTSCs must be eradi-
cated in order to radically cure brain tumors. In this
experiment, BTSCs are taken as the therapeutic target
to study the effect of ATRA on the proliferation and dif-
ferentiation of BTSCs, evaluating the antitumor activity
of ATRA from a brand-new perspective.
Materials and methods
1 Major reagents and instruments
(1) Major reagents: DMEM/F12 and B27 were pur-
chased from Gibco(U.S.A). Epidermal growth factor
(EGF) and basic fibroblast growth factor (bFGF) were
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purchased from PeproTech (U.S.A.). ATRA,3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
(MTT), fetal bovine serum (FBS), trypsin, Cy3-labeled
sheep anti-rabbit IgG and diamidino-phenyl-indole
(DAPI) were all purchased from Sigma (U.S.A). Rabbit
anti-human CD133 antibody was purchased from
Abcam (U.S.A). Rabbit anti-glial fibrillary acidic protein
(GFAP) antibody and FITC-labeled goat anti-rabbit IgG
were purchased from Boster (Wuhan, China).
(2) Major instruments: BB16 CO2 incubator and HF-
safe-1200 purifying worktable (Heraeus and Lishen com-
pany, Germany). CKX41 inverted phase contrast micro-
scope, BX51 fluorescence microscope and imaging
system (Olympus, Japan). ELISA Reader 2010 (Anthos,
Austria).
2 Experimental methods
(1) Isolation, culture and purification of BTSCs: The tis-
sue samples were obtained from 3 surgical patients in
Department of Neurosurgery, Anhui Provincial Hospital
Affiliated to Anhui Medical University who had been
diagnosed with glioblastoma during February-May, 2009.
Fresh glioblastoma tissues without cystic degeneration,
necrosis, calcification and electric coagulation were
resected from the margin of tumor. By method in Ref
[2], fresh glioblastoma tissues without cystic degenera-
tion, necrosis, calcification and electric coagulation were
resected from the margin of tumor, put in simplified
serum-free medium (DMEM/F12, containing 2% B27, 20
g/L EGF and 20 g/L bFGF), and trimmed off necrotic
tissues and residual blood vessels. After rinsing with
serum-free medium for three times, the tissue masses
were cut into pieces, disaggregated into single cell sus-
pensions by using a Pasteur pipette (blowing repeatedly),
and filtered with a sieve with the aperture of 74 m. The
filtered single cell suspensions were stained with Trypan
Blue. The living cells were counted, and primary culture
was completed within 2 h, followed by inoculation in
simplified serum-free medium (DMEM/F12, containing
2% B27, 20 μg/L EGF and 20 μg/L bFGF), and then cul-
ture at 37°C in 5% CO2 saturated humidity incubator.
The medium was changed every 3~4 days. The cells
were passaged by 1:2 subculture every 7 days and
observed under the inverted phase contrast microscope.
The cells were passaged three times. After the cell
spheres became regularly shaped, they were dissociated
into single cells with 0.25% trypsin + mechanical
method, and inoculated into a 96-well plate at 1 living
cell/well, with each well added with 100 μL simplified
serum-free medium. The wells containing only one cell
were labeled under the inverted microscope, and supple-
mented with 100 μL simplified serum-free medium for
further culture. The formation of single cell colonies
was recorded by dynamic observation. The cells were
observed under the inverted microscope after culture
for about one week, and the proliferated cells were col-
lected and transferred into a culture flask for further
culture and proliferation. The purified BTSCs after col-
ony screening were used in the following experiments.
(2) Immunofluorescent identification of BTSCs: On the
5th day of passage, BTSs that grew well were re-suspended
in culture medium containing a small amount of serum
(DMEM/F12 containing 10%FBS), and dropped onto a
poly-L-lysine-coated coverslip. After standing still for
about 4 h until the solution adhered to the coverslip, the
coverslip was fixed in 4% paraformaldehyde for 30 min,
blocked with normal goat serum for 20 min, incubated
with rabbit anti-human CD133 antibody overnight at 4°C,
and then incubated with Cy3-labeled sheep anti-rabbit
IgG at 37°C for 60 min, followed by DAPI counterstaining
of the nuclei and coverslipping with buffered glycerol. Fol-
lowing each step, the coverslip was rinsed with 0.01 mol/L
PBS three times, each for 5 minutes. The coverslip was
observed after mounting and pictures were taken.
(3) Assessment of the effect of ATRA on proliferation
of BTSCs: The BTSCs were collected and divided into
groups as described below, put into the corresponding
culture medium, disaggregated into single cell suspen-
sions by mechanical dissociation, and inoculated into a
96-well plate at the density of 1000 living cells/well, with
100 Ml in each well. According to the different treat-
ments, the BTSCs were divided into: (1) control group:
basic medium (DMEM/F12 with 2% B27) containing the
same amount of anhydrous ethanol as in the ATRA
group (the final concentration < 0.1%); (2) ATRA group:
containing 1 μmol/L ATRA; (3) ATRA/growth factor
group: containing 1 μmol/L ATRA, and 20 μg/L EGF and
20 μg/L bFGF; (4) growth factor group: containing 20 μg/
L EGF and 20 μg/L bFGF. The cells in the plate were
then cultured at 37°C in 5% CO2 saturated humidity
incubator, each well was added with the corresponding
medium 20 μL every other day, and the cell proliferation
was observed under the inverted microscope every day.
MTT assay was performed to evaluate the proliferation
consecutively from the 1st to the 9th day of culture. Each
well was added with 20 μL MTT solution (5 g/L), and the
cells were cultured for 4 h, followed by 10 min centrifu-
gation at 1000r/min. The supernatant in the wells was
absorbed carefully and discarded. Each well was added
with 150 μL DMSO. After shaking for 10 min to achieve
dissolution and crystallization, the optical density value
of each well was measured by ELISA at the wavelength of
570 nm. Six duplicate wells were set up for each group.
The experiments were repeated 3 times, and the averages
were obtained.
(4) Assessment of the effect of ATRA on differentia-
tion of BTSCs: The collected BTSCs were adjusted to
2 × 105 living cells/mL using serum-containing medium
Niu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:113
http://www.jeccr.com/content/29/1/113
Page 2 of 9
(DMEM/F12 containing 10%FBS), and inoculated into a
6-well plate with PLL-coated coverslips, with 2 mL in
each well. The cells were divided into two groups: (1)
ATRA group: serum-containing medium added with
ATRA with the final concentration of 1 μmol/L; (2)
control group: serum-containing medium containing the
same amount of anhydrous ethanol as in the ATRA
group (the final concentration < 0.1%). The cells were
cultured at 37°C in 5% CO2 saturated humidity incuba-
tor. The culture medium was changed every 3 days. The
growth and differentiation of BTSCs were observed
dynamically.
(5) Immunofluorescent detection of the differentiated
BTSCs: The coverslips were taken out on the 10th day of
induction, fixed in 40 g/L paraformaldehyde for 30 min,
blocked with normal goat serum for 20 min (those for
GFAP staining were treated with 0.3%Triton X-100 for
20 min before serum blocking), incubated with anti-
CD133 or anti-GFAP antibody overnight at 4°C, and then
incubated at 37°C for 60 min with Cy3-labeled and
FITC-labeled secondary antibodies respectively, followed
by DAPI counterstaining of the nuclei and mounting
with buffered glycerol. Following every step, the cover-
slips were rinsed with 0.01 mol/L PBS three times, each
for 5 minutes. Randomly, 20 microscopic fields were
selected on each coverslip and investigated under the
fluorescence microscope to calculate the percentages of
CD133 and GFAP positive cells among adherent cells.
The calculation formula is: percentage of CD133 (or
GFAP) positive cells = (CD133 (or GFAP) positive cells)/
(DAPI positive cells)× 100%.
(6) Proliferation of the differentiated BTSCs: The
adherent cells of the above two groups after 10 days of
induction were digested with 0.25% trypsin, added with
simplified serum-free medium, and inoculated into a 96-
well plate at 5 living cells/well (density adjusted by lim-
ited dilution), with each well added with 100 μL simpli-
fied serum-free medium. The cells were then cultured at
37°C in 5% CO2 saturated humidity incubator. Each well
was added with 20 μL simplified serum-free medium
every other day, and the BTS formation was observed.
The sphere formation and growth rate were observed at
specified times every day, and the emergence of regu-
larly-shaped BTSs (containing over 10 cells) was consid-
ered as positive result. The time required for BTS
formation and the number of BTSs were recorded and
used to calculate the percentage of BTS and the time
for colony formation. The formed BTSs were dropped
on PLL-coated coverslips to be dried for CD133 immu-
nofluorescence staining as described previously.
3 Statistical analysis
All experimental data were expressed by mean ± stan-
dard deviation (x¯ ± s). The software of SPSS version
16.0 was used for data analysis. An independent t-test
was conducted for comparison between groups, and
one-way ANOVA with Dunnett t test was used to com-
pare the growth curves of different groups. P ≤ 0.05 was
considered statistically significant.
Results
1 BTS formation from proliferation of a single BTSC
The whole process of BTS formation from the prolifera-
tion of a single BTSC by limited dilution could be
observed under the inverted microscope (Fig. 1). After
1-2 days of inoculation, it could be observed that the
single cells splitted to form cell colonies consisting of
2~several cells. The cells in the colonies were round,
with similar size. After 2~3 days, more cells formed
colonies, and 4~5 days later, cell spheres composed of
dozens to hundreds of cells were observed. The cell
spheres were spherically shaped or elliptically shaped,
with uniform structures and high transmittance. BTSCs
are different from ordinary tumor cells due to their self-
renewal and proliferation potential, and CD133 plays an
important role in identifying whether BTSCs have the
characteristics of stem cells, so cell spheres formed from
the proliferation of a single cell were stained with
CD133. It can be found that cell spheres were CD133
positive (Fig. 2), proving that the cultured cell spheres
were composed of BTSCs with characteristics of stem
cells. They could now be called BTS, which was the
colonial sphere of a great number of sub-cell lines from
the same cell, so the proportion of non-BTSCs was low,
and the purity was high.
2 Proliferation of BTSCs promoted by ATRA
BTSCs in the growth factor group began to proliferate
after 1~2 days of culture, forming cell spheres composed
of 10~20 cells. The cells exhibited rapid suspended
growth thereafter, and the cell spheres gradually got lar-
ger. Seven days later, dozens to hundreds of cells aggre-
gated to form sphere-like structures with distinct
boundary and high refraction. Cell proliferation
occurred after 2~3 days of culture in the ATRA/growth
factor group. The cell growth in this group was almost
the same as in the growth factor group, but the number
and volume of the cell spheres formed were slightly
smaller than those in the growth factor group. Cell pro-
liferation also occurred after 2~3 days in the ATRA
group, with the cell spheres exhibiting suspended
growth, but only cell masses consisting of dozens of
cells were observed during the whole process. The
volume of the cell spheres was larger than that in the
control group, but obviously smaller than that in the
growth factor group and the ATRA/growth factor
group. The cell proliferation in the control group was
relatively slower, and the formed colonies were smaller,
Niu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:113
http://www.jeccr.com/content/29/1/113
Page 3 of 9
merely consisting of a dozen cells (Fig. 3). No obvious
adherent differentiation was observed in any group.
With the mean of optical density values measured for
each group as the vertical axis, and the growth days as
the horizontal axis, the growth curves of BTSCs for dif-
ferent groups were plotted (Fig. 4) to compare the cell
proliferation rates of the four groups. It can be observed
that, on the 1st-3rd day, the growth curves of all the four
groups rise slowly, with an insignificant difference in the
cell proliferation rate. From the 3rd day, the cell
proliferation obviously become more rapid, and the
growth curves of the four groups begin to separate from
each other. The curve is steep during the 5th~7th days,
indicating the peak of proliferation. Cell proliferation is
slowest in the control group, obviously faster in the
ATRA group, and fastest in the growth factor group,
and the proliferation rate of the ATRA/growth factor
group is slightly lower than that of the growth factor
group, but significantly higher than that of the ATRA
group. It is indicated that ATRA had a promotive effect
Figure 1 BTS resulting from the proliferation of a single BTSC(Inverted phase-contrast microscope, × 400). 1A:an hour after inoculated.
1B: 12 hours after inoculated. 1C: 24 hours after inoculated. 1D: 3 days hours after inoculated.
Figure 2 Immunofluorescent identification of BTSCs for CD133 (Cy3, × 200). 2A: DAPI. 2B:CD133. 2C:Merge. It showed the cell spheres were
CD133 positive.
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on the proliferation of suspended BTSCs, but had no
obvious synergistic or antagonistic effect with the
growth factor.
3 Differentiation of BTSCs promoted by ATRA
It can be observed under ordinary light microscope
that, after 6 h, BTSCs of both groups were adherent,
and generated small protuberances toward outside.
With the prolonging of the protuberances, the pro-
tuberances of the adjacent cells formed a netlike con-
nection. The BTSCs grew larger, becoming different in
size and shape, exhibiting the shapes of polygon, spin-
dle and roundness, and being transparent under micro-
scope, with high refraction. DAPI staining showed that
the nuclei had different sizes and shapes, with signifi-
cant atypia. There was no obvious increase in the
adherent cells, indicating that proliferation of BTSCs
was inhibited in the serum-containing medium, and
cell differentiation was dominant. CD133 and GFAP
immunofluorescence detection of the expression per-
centages after 10 days of induction by ATRA showed
that CD133 expression did not disappear in both
groups, indicating that BTSCs did not achieve terminal
differentiation, and had the characteristics of being dif-
ferentiated incompletely. But compared to the control
group, the CD133 expression in the ATRA group was
lower, and the GFAP expression was higher, the differ-
ences being significant (P < 0.05) (Fig. 5, 6, Table 1). It
is indicated that ATRA can induce the differentiation
of BTSCs, however, can not help the BTSCs to achieve
terminal differentiation, but instead can promote the
proliferation and self-renewal of BTSCs.
4 Reduction of proliferation of the differentiated BTSCs
by ATRA
Within 24 hours after the differentiated BTSCs were
transferred into the simplified serum-free medium, a
majority of cells became adherent and generated pro-
tuberances, with a minority suspending in the medium.
After 2 days of culture, some of the suspended cells in
the control group proliferated to form cell masses.
After 3~6 days, more cells aggregated to form masses,
and a great number of suspended cell masses emerged
one after another, which consisted of a dozen cells at
first, and gradually grew larger with the lapse of time
and became sphere-shaped, with each sphere com-
posed of 100~200 cells of similar size. In the ATRA
group, suspended cell masses began to appear on the
9th day, and gradually increased in number during the
following 3~4 days, but the formed spheres had
Figure 3 The volume of the cell spheres formed in different group(Inverted phase-contrast microscope, × 400). 2A: the control group.
2B: the ATRA group. 2C: the ATRA/growth factor group. 2D: the growth factor group.
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smaller diameters and slower growth rate. Table 1
shows that the percentage of BTS formation in the
ATRA group was (4.84% ± 0.32%), significantly lower
than that in the control group (17.71% ± 0.78%) (P <
0.05), and the time required for BTS formation in the
ATRA group was (10.07 ± 1.03)d, significantly longer
than that in the control group (4.08 ± 0.35)d (P <
0.05). The BTSs obtained from differentiated BTSCs
were CD133 positive (Fig. 7), indicating that stem cell
phenotype was restored again. Accordingly, the differ-
entiated BTSCs induced by ATRA did not accomplish
terminal differentiation and lose the proliferation cap-
ability. ATRA can induce the differentiated BTSCs into
more mature ones, but the induction is not thorough
and complete, and terminal differentiation cannot be
achieved.
Discussions
Ever since Singh et al discovered BTSCs for the first
time in 2003[2], many scholars have confirmed that
BTSCs exist in the brain tumor tissue and its cell lines,
and possess the potential of self-renewal, unlimited pro-
liferation, multilineage parent differentiation and high
tumorigenicity[3-6]. In 2004, Galli et al and Singh et al
proposed a new tumorigenesis model, believing that
BTSCs were the initiating cells of tumor formation[4,5].
These BTSCs proliferated and differentiated following
the same symmetric and asymmetric division rule as
neural stem cells, namely, accomplishing self-renewal
and proliferation by symmetric division, and producing
relatively mature progeny cells by asymmetric division
which can be differentiated into more mature tumor
cells.
Induction of differentiation of glioma cells into benign
ones has been one of the research focuses of glioma
therapy in recent years. The application of differentia-
tion inducers can increase the differentiation of the
tumor cells and inhibit proliferation. ATRA, as a classic
differentiation inducer, has achieved a very good cura-
tive effect in clinical treatment of hematological neo-
plasms and lymphoma. In vitro study has indicated that
ATRA can induce the differentiation and apoptosis of a
variety of glioma cells[7]. Many researches have con-
firmed that BTSCs are able to self renew and proliferate
continuously when cultured in serum-free medium con-
taining growth factor, retaining the inherent feature of
stem cells, but differentiate into tumor cells with the
shape and molecular phenotype resembling the parental
tumor under serum-containing conditions[2-6]. This
study has used BTSCs as the therapeutic target to
investigate the effect of ATRA on the proliferation and
differentiation of BTSCs both in the serum-free and
serum-containing mediums.
BTSCs with a high purity must be obtained first in
order to do research on BTSCs. Currently, the method
of immunomagnetic bead separation is often used to
Figure 4 Growth curves of BTSCs in different groups(the mean
of optical density values measured for each group as the
vertical axis, and the growth days as the horizontal axis). The
results are shown as mean ± SD of four different experiment. Data
of each day was analyzed by one-way ANOVA with Dunnett t test.
The growth curves of the ATRA group, ATRA/growth factor group
and growth factor group rise faster than that of the control group(P
< 0.01). While there were no statistically significant between the
ATRA/growth factor group and growth factor group(P > 0.05).
Figure 5 Immunofluorescence staining of differentiated BTSCs for CD133 (Cy3, × 200). 5A: DAPI. 5B:CD133. 5C:Merge. It showed the
CD133 expression of differentiated BTSCs induced by ATRA did not disappear.
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obtain CD133-positive BTSCs at home and abroad,
which is expensive and has a primary isolation efficiency
of merely 46.9%~79.8%[3]. Che Xiaoming et al achieved
similar outcomes by colony selection with the use of
limited dilution, and harvested about 82% cells that have
the proliferation capacity[2]. We obtained highly puri-
fied BTSCs by their method.
As is known to all, EGF and bFGF, as powerful promo-
ters of cell division, are essential key components in stem
cell culture medium, and enable stem cells to proliferate
continuously. Through MTT experiment, we have found
that ATRA alone can promote the proliferation of
BTSCs, but the promoting effect is weaker than EGF
+bFGF, and there is no obvious synergistic or antagonis-
tic effect between ATRA and EGF+bFGF. Previous
researches have showed that ATRA can inhibit the prolif-
eration of ordinary glioma cells cultured in serum-con-
taining medium, promoting apoptosis of the glioma cells.
We have observed that BTSCs in the control group grew
as suspended spheres when cultured in the medium with-
out serum and growth factors. Similar to the control
group, BTSCs in the ATRA group were not adherent, but
the formed spheres were larger and the proliferation was
more rapid, indicating that ATRA did not induce the dif-
ferentiation of the suspended BTSCs, but promote the
proliferation of BTSCs. The reason may be as mentioned
below. In the serum-free medium, BTSCs can achieve
continuous self renewal and proliferation through sym-
metric division, retaining the stem cell characteristics;
and in the serum-containing medium, because of the
influence of certain substance in the serum, BTSCs can
retain their existence through asymmetric division, and
produce a great number of comparatively mature pro-
geny cells, which differentiate into ordinary tumor cells
ultimately, so there is only a small percentage of BTSCs
in the whole cell population. The targets of ATRA’s effect
of differentiation induction are cells in the process of dif-
ferentiation. For BTSCs in the stem cell state, ATRA has
a promoting effect on their proliferation. So ATRA exerts
opposite effects on BTSCs at different stages of differen-
tiation, the mechanism of which needs further clarifica-
tion. Clinical trials of differentiation of brain glioma cells
induced by ATRA showed that the differentiation effect
of ATRA alone was weak, with insignificant curative effi-
cacy[8,9]. We speculate that the application of ATRA
alone can induce the differentiation and apoptosis of
most ordinary glioma cells, but promote the proliferation
of a minority of BTSCs that does not experience differen-
tiation, that is to say, the “seeds” resulting in the forma-
tion, development and relapse of tumors do not decrease
but increase, which may be exactly the major reason for
the poor therapeutic effect.
Research of Singh et al revealed that only CD133 posi-
tive cells had the stem cell characteristics of self-renewal,
unlimited proliferation and multilineage parent differen-
tiation[3]. These days, CD133 has been recognized as the
marker to isolate and identify BTSCs. And the astrocyte
marker GFAP is one of the major markers for the differ-
entiated progeny of BTSCs, and GFAP expression is also
increased after glioma cells differentiate into mature
Figure 6 Immunofluorescence staining of differentiated BTSCs for GFAP (FITC, × 200). 6A: DAPI. 6B:GFAP. 6C:Merge. It showed the
differentiated BTSCs induced by ATRA were GFAP positive.
Table 1 The expressions of the markers, percentage and time of BTS formation in the differentiated BTSCs(n = 3,
Mean ± SD)
Group CD133 (%) GFAP(%) the percentage of BTS the time of formation
control group 7.05 ± 0.49 12.51 ± 0.77 17.71 ± 0.78 4.08 ± 0.35
ATRA group 2.29 ± 0.27 75.60 ± 4.03 4.84 ± 0.32 10.07 ± 1.03
T value 14.737 26.634 26.440 9.537
P value 0.000 0.000 0.000 0.001
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ones. Engelhard et al found that the loss of GFAP expres-
sion could promote the malignant phenotype of cells and
accelerate the development of glioma, whereas the up-
regulation of GFAP expression could promote the differ-
entiation of glioma, reducing the malignancy[10]. Toda
et al [11], after tranfecting rat C6 glioma cell line with
GFAP cDNA, found that the cell growth was inhibited
and GFAP expression increased, showing a differentia-
tion trend, and believed that GFAP gene could inhibit
tumors. Besides, some negative regulator genes of cell
cycles can also induce differentiation through GFAP gene
[11]. For instance, transfection of P21WAF1/CIP1 gene
can enhance the GFAP expression, thus enabling the
tumor cells to achieve terminal differentiation [12].
Accordingly, we used CD133 and GFAP to examine the
induction effect of ATRA on the differentiation of BTSCs
from the level of molecular biology. BTSCs differentiated
in serum-containing medium, and the differentiated
BTSCs expressed more GFAP and less CD133 with the
addition of ATRA, and meanwhile the proliferation abil-
ity was reduced. It can be believed that ATRA induces
the differentiation of BTSCs into more mature ones, and
prevents the differentiated BTSCs from differentiating to
form more BTS, reducing the differentiation capacity of
BTSCs to a certain extent. Therefore, ATRA has a dual
effect on BTSCs: (1) multiplying BTSCs by promoting
proliferation and self renewal; (2) inducing differentiation
of the differentiated BTSCs into more mature ones
through indirectly up-regulating the GFAP expression.
It has been found in this study that CD133 expression
did not disappear after differentiation of BTSCs
induced by ATRA in serum-containing medium. The
differentiated BTSCs were still able to differentiate and
proliferate to form BTSs after being inoculated into
serum-free medium that was added with growth factors.
However, after differentiation of NSCs, though cells
with the NSC phenotype still exist among the differen-
tiated cells, they don’t have the ability of re-forming
neurospheres[13]. These abnormal phenomena indicate
that ATRA-induced differentiation therapy fails to
achieve terminal differentiation of BTSCs and enable
them to lose the proliferation ability, and the differen-
tiated BTSCs can restore the characteristics of stem
cells under certain conditions, which may be the major
reason for the poor effect of this therapy. With the dee-
pening of the investigation into BTSCs, the key to
achieve breakthrough in this area is to further reveal the
molecular mechanism of the proliferation and differen-
tiation of BTSCs and develop the differentiation inducer
specific for BTSCs.
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